KAS
DNLI icon

Kestra Advisory Services’s Denali Therapeutics DNLI Stock Holding History

Kestra Advisory Services’s Portfolio DNLI Stock Details DNLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-3,430
Closed -$294K – 1897
2020
Q4 		$294K Buy
+3,430
New +$207K ﹤0.01% 1480

Other funds holding DNLI

Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
CM
Crestline Management Fort Worth, Texas $46.3M AUM 48.82% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return
GGHC
Gilder Gagnon Howe & Co New York $8.34B AUM 46.58% 1-Year Est. Return
FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Kestra Advisory Services's DNLI Position: Q1 2021 in Review

Kestra Advisory Services sold out of Denali Therapeutics (DNLI) in Q1 2021, closing a stake of 3,430 shares — an estimated $294K sold.

Kestra Advisory Services first reported a position in DNLI in Q4 2020 and held it in 1 quarter. The position peaked at $294K in Q4 2020. 216 funds tracked by Wall St. Rank hold DNLI as of Q1 2021.

  • Kestra Advisory Services reported no remaining Denali Therapeutics position as of Q1 2021 after selling out during the quarter.
  • Kestra Advisory Services sold 3,430 Denali Therapeutics shares in Q1 2021, an estimated $294K.
  • Kestra Advisory Services first reported a position in Denali Therapeutics in Q4 2020 and held it in 1 quarter.
  • Kestra Advisory Services's Denali Therapeutics position peaked at $294K in Q4 2020.
  • 216 funds tracked by Wall St. Rank held Denali Therapeutics as of Q1 2021.

Based on Kestra Advisory Services's 13F filing for Q1 2021, filed 10 May 2021.